Minimally invasive joint reconstruction product line
addresses fundamental issue of joint damage
HUNTINGTON BEACH, Calif., (July 24, 2020) — Subchondral Solutions, Inc., a medical device company based in Huntington Beach, Calif., has received 510(k) Food and Drug Administration (FDA) clearance for its S-Core™ core-preserving Osteochondral Reconstruction System. S-Core™ is the first and only hydroxyapatite-coated (HA), bone-preserving, fenestrated and cannulated family of implants specifically designed for minimally invasive joint reconstruction, with FDA clearance.
“This regulatory clearance has enabled the company to begin commercialization of its suite of products in the U.S.,” says Derek T. Dee, M.D., orthopedic surgeon and device developer who has successfully performed multiple procedures using the product. “I find osteochondral damage in many of my sports medicine procedures, and until now did not have the technology to repair them.”
S-Core™ can be used in any osteochondral fracture appropriate for the size of the device, including the knee, elbow, hand, foot, ankle, shoulder and hip. The S-Core™ technology is indicated for minimally invasive joint reconstruction and fixation of small bone fragments, such as osteochondral fragments and cancellous fragments including simple metaphyseal fractures; condylar fractures; osteochondritis dissecans; areas where accurate screw placement is vital; patellar fractures, navicular fractures, intra-articular fractures and osteochondral fixation and fractures, as well as ligament fixation.
“We are developing a line of products that will address the fundamental issues of joint damage, including restoring the biomechanical function of the entire osteochondral unit, as well as creating an effective platform for healing,” says Dr. Dee. “Our focus is on developing a platform of restorative technology for joint damage using bio-active implants.”
About Subchondral Solutions, Inc.
Subchondral Solutions is developing a proprietary platform technology and is committed to advancing the treatment of joint damage by addressing the source of the problem with a biomechanical, efficient, cost-effective scalable system. As many as 27 million Americans suffer from joint damage in the knee annually; the majority of existing treatments are palliative and do not creative a long-term solution for patients.
Subchondral Solutions has an extensive worldwide patent portfolio with issued and published intellectual property reflecting this innovative approach to the treatment of joint damage. A family of devices for the entire spectrum of joint damage is reflected in the patent roadmap.
Tom Kinder, CEO, Subchondral Solutions